Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) to meet unmet patient needs [3] - The company collaborates with leading academic institutions and biopharmaceutical companies to create transformative medicines for serious diseases [3] Recent Developments - OSE Immunotherapeutics has launched its inaugural Newsletter aimed at individual shareholders and investors, marking the 10th anniversary of its listing on Euronext Paris [2] - The Newsletter will provide updates on company developments, insights into team efforts, and deeper discussions on topics typically covered in press releases [2] Communication Strategy - The Newsletter will be published regularly in both French and English and will be accessible in the "Investors" section of the OSE Immunotherapeutics website [2] - This initiative is intended to enhance communication with individual shareholders and express appreciation for their continued support [2]

Core Points - OSE Immunotherapeutics has requested an extension for the Combined General Meeting scheduled for June 25, 2025, to ensure a regular and transparent process for shareholders [1][2][6] - The request is in response to shareholder concerns regarding the timely communication of resolutions aimed at changing the Board of Directors' composition [2][3] - The resolutions presented by a group of shareholders acting in concert have been renumbered from n°35 to 44 to A to K, with the content remaining unchanged [4] Company Information - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation [8] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [8] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [8]